Literature DB >> 26493554

Perinatal survival and procedure-related complications after intrauterine transfusion for red cell alloimmunization.

Dipika Deka1, Vatsla Dadhwal2, Aparna K Sharma1, Unnati Shende1, Sumita Agarwal1, Ramesh Agarwal1, Perumal Vanamail1.   

Abstract

OBJECTIVES: To study the perinatal survival and procedure-related (PR)complications after intrauterine transfusions in red cell alloimmunization.
METHODS: Prospective data of 102 women with Rh-alloimmunized pregnancy undergoing intrauterine intravascular transfusion for fetal anemia, from January 2011 to October 2014 were analyzed. Main outcome measures were perinatal survival and procedure-related (PR) complications.
RESULTS: A total of 303 intrauterine transfusions were performed in 102 women. Of 102 fetuses, 22 were hydropic at first transfusion. The mean period of gestation and hematocrit at first transfusion was 26.9 ± 3.3 weeks (range 19.7-33.8 weeks) and 17 ± 7.82 % (range 5.7-30 %), respectively. Average number of transfusions was 2.97 (range 1-7) per patient. Overall survival was 93 % and mean period of gestation at delivery was 34.5 ± 1.94 (range 28.3-37.4) weeks. Mean hematocrit at delivery was 36.9 ± 8.77 % (range 10-66 %). Fetal death occurred in four cases (3PR), neonatal death occurred in three cases (2PR). Emergency cesarean delivery after transfusion was performed in four pregnancies. The total PR complication rate was 2.97 %, resulting in overall PR loss in 1.65 % per procedure.
CONCLUSION: Our results compare favorably with other studies published in the literature. Intravascular transfusion is a safe procedure improving perinatal survival in fetuses with anemia due to Rh-alloimmunization.

Entities:  

Keywords:  Fetal anemia; Fetal therapy; Intrauterine transfusion; Red blood cell alloimunization

Mesh:

Year:  2015        PMID: 26493554     DOI: 10.1007/s00404-015-3915-7

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  Perinatal Outcome After Intrauterine Transfusion in Rh Isoimmunized Mothers.

Authors:  Omkar Potdar; Hemraj R Narkhede; Purnima R Satoskar
Journal:  J Obstet Gynaecol India       Date:  2018-04-02

2.  NT-proBNP: A Useful Biochemical Marker for Prognosis in Rh-Isoimmunized Pregnancies.

Authors:  Vikas Yadav; Dipika Deka; Sharma Aparna; Vatsla Dadhwal
Journal:  J Obstet Gynaecol India       Date:  2018-10-01

3.  Intrauterine Fetal Blood Transfusion: Descriptive study of the first four years' experience in Oman.

Authors:  Arwa Z Al-Riyami; Mouza Al-Salmani; Sabria N Al-Hashami; Sabah Al-Mahrooqi; Ali Al-Marhoobi; Sumaiya Al-Hinai; Saif Al-Hosni; Sathiya M Panchatcharam; Zainab A Al-Arimi
Journal:  Sultan Qaboos Univ Med J       Date:  2018-04-04

4.  Efficacy of Antenatal Intravenous Immunoglobulin Treatment in Pregnancies at High Risk due to Alloimmunization to Red Blood Cells.

Authors:  Beate Mayer; Larry Hinkson; Wiebke Hillebrand; Wolfgang Henrich; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2018-10-31       Impact factor: 3.747

5.  Sonographic Demonstration of Intracranial Hemorrhage in a Fetus with Hydrops Fetalis due to Rh Alloimmunization after Intrauterine Intravascular Transfusion: A Case Report and Review of the Literature.

Authors:  Rauf Melekoglu; Ebru Celik; Hasim Kural
Journal:  Case Rep Obstet Gynecol       Date:  2018-03-26

6.  The near disappearance of fetal hydrops in relation to current state-of-the-art management of red cell alloimmunization.

Authors:  Carolien Zwiers; Dick Oepkes; Enrico Lopriore; Frans J Klumper; Masja de Haas; Inge L van Kamp
Journal:  Prenat Diagn       Date:  2018-09-27       Impact factor: 3.050

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.